LUCD vs. LAKE, SKIN, KRMD, BWAY, INFU, SGHT, NVRO, PDEX, TLSI, and ZJYL
Should you be buying Lucid Diagnostics stock or one of its competitors? The main competitors of Lucid Diagnostics include Lakeland Industries (LAKE), Beauty Health (SKIN), KORU Medical Systems (KRMD), BrainsWay (BWAY), InfuSystem (INFU), Sight Sciences (SGHT), Nevro (NVRO), Pro-Dex (PDEX), TriSalus Life Sciences (TLSI), and Jin Medical International (ZJYL). These companies are all part of the "medical equipment" industry.
Lucid Diagnostics vs.
Lakeland Industries (NASDAQ:LAKE) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap industrial products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, community ranking, analyst recommendations, earnings and valuation.
Lakeland Industries currently has a consensus price target of $27.50, suggesting a potential upside of 5.65%. Lucid Diagnostics has a consensus price target of $3.63, suggesting a potential upside of 330.11%. Given Lucid Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe Lucid Diagnostics is more favorable than Lakeland Industries.
In the previous week, Lakeland Industries had 2 more articles in the media than Lucid Diagnostics. MarketBeat recorded 3 mentions for Lakeland Industries and 1 mentions for Lucid Diagnostics. Lakeland Industries' average media sentiment score of 0.64 beat Lucid Diagnostics' score of -0.25 indicating that Lakeland Industries is being referred to more favorably in the media.
Lakeland Industries has higher revenue and earnings than Lucid Diagnostics. Lakeland Industries is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
Lakeland Industries has a net margin of -0.42% compared to Lucid Diagnostics' net margin of -1,069.87%. Lakeland Industries' return on equity of 1.66% beat Lucid Diagnostics' return on equity.
71.7% of Lakeland Industries shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 4.2% of Lakeland Industries shares are held by insiders. Comparatively, 8.8% of Lucid Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Lakeland Industries has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500.
Lakeland Industries received 166 more outperform votes than Lucid Diagnostics when rated by MarketBeat users. However, 67.92% of users gave Lucid Diagnostics an outperform vote while only 61.77% of users gave Lakeland Industries an outperform vote.
Summary
Lucid Diagnostics beats Lakeland Industries on 10 of the 19 factors compared between the two stocks.
Get Lucid Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LUCD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lucid Diagnostics Competitors List
Related Companies and Tools
This page (NASDAQ:LUCD) was last updated on 1/20/2025 by MarketBeat.com Staff
